High MICAL1 Expression Correlates with Cancer Progression and Immune Infiltration in Renal Clear Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Dec 27

PMID 36575439

Authors

Yixing Yang

Fengwen Ye

Tianxiang Xia

Qianwen Wang

Jun Du

Affiliations

Soon will be listed here.

Abstract

Background: Molecule interacting with CasL 1 (MICAL1), a multidomain flavoprotein monooxygenase, is strongly involved in the biological processes related to cancer cell proliferation and metastasis. However, there were few reports on the clinical significance of MICAL1 in renal clear cell carcinoma.

Methods: The expression and prognostic value of MICAL1 in renal clear cell carcinoma were explored using immunohistochemical assays, public TCGA-KIRC databases and multiple analysis methods, including survival analysis, univariate and multivariate analyses, KEGG and GSEA. Wound healing and Transwell assays were performed to check the 786-O cell and Caki-1 cell migration abilities after knockdown of MICAL1. Western blotting was used to assess the regulatory effect of MICAL1 on the Rac1 activation. Additionally, the function of MICAL1 and the correlations between MICAL1 and immune infiltration levels in KIRC were investigated using TIMER and TISIDB.

Results: MICAL1 expression was significantly higher in carcinoma tissue compared with non-cancerous tissue. A survival analysis revealed that patients with high MICAL1 expression had shorter overall survival (OS) and disease-specific survival (DSS) compared with patients with low MICAL1 expression. ROC analysis also confirmed that MICAL1 has a high diagnostic value in KIRC. Importantly, the univariate and multivariate Cox analysis further confirmed that high MICAL1 expression was an independent risk factor for OS in patients with KIRC. In accordance with this, knockdown of MICAL1 expression decreased Rac1 activation and cell migration. KEGG and GSEA analysis revealed that the immune infiltration and Ras signaling pathways were significantly upregulated in the high MICAL1 expression group. In terms of immune infiltrating levels, MICAL1 expression was positively associated with CD8+/Treg cell infiltration levels. Specifically, bioinformatic analysis showed that MICAL1 expression had strong relationships with various T cell exhaustion markers.

Conclusions: MICAL1 expression may act as a prognostic biomarker for determining the prognosis in renal clear cell carcinoma and plays an important role in regulating tumor immune microenvironment and cell migratory capacity.

Citing Articles

MICAL1 Mediates TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Activating Smad2/3.

Zhuang X, Wang C, Ge Z, Wu M, Chen M, Chen Z Cell Biochem Biophys. 2025; .

PMID: 39954154 DOI: 10.1007/s12013-025-01668-8.

High expression of ACKR1 predicts a good prognosis and suppresses sarcoma cell progression via regulating the tumor immune microenvironment.

Lin J, Liang F, Zheng L, Zeng J, Lin J J Appl Genet. 2023; 65(1):121-136.

PMID: 38006471 DOI: 10.1007/s13353-023-00805-4.

References

Min P, Zhao S, Liu L, Zhang Y, Ma Y, Zhao X . MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration. J Cell Mol Med. 2019; 23(6):4475-4488. PMC: 6533512. DOI: 10.1111/jcmm.14353. View

Yoon J, Terman J . MICAL redox enzymes and actin remodeling: New links to classical tumorigenic and cancer pathways. Mol Cell Oncol. 2018; 5(1):e1384881. PMC: 5791864. DOI: 10.1080/23723556.2017.1384881. View

Niu F, Sun K, Wei W, Yu C, Wei Z . F-actin disassembly factor MICAL1 binding to Myosin Va mediates cargo unloading during cytokinesis. Sci Adv. 2020; 6(45). PMC: 7673715. DOI: 10.1126/sciadv.abb1307. View

Giridharan S, Caplan S . MICAL-family proteins: Complex regulators of the actin cytoskeleton. Antioxid Redox Signal. 2013; 20(13):2059-73. PMC: 3993057. DOI: 10.1089/ars.2013.5487. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Ma Q, Liu J, Wu G, Teng M, Wang S, Cui M . Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients. Clin Exp Pharmacol Physiol. 2018; 45(10):1002-1009. DOI: 10.1111/1440-1681.12992. View

Lucken-Ardjomande Hasler S, Vallis Y, Pasche M, McMahon H . GRAF2, WDR44, and MICAL1 mediate Rab8/10/11-dependent export of E-cadherin, MMP14, and CFTR ΔF508. J Cell Biol. 2020; 219(5). PMC: 7199855. DOI: 10.1083/jcb.201811014. View

Deng W, Wang Y, Zhao S, Zhang Y, Chen Y, Zhao X . MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway. J Cell Mol Med. 2018; 22(6):3108-3118. PMC: 5980113. DOI: 10.1111/jcmm.13588. View

10.

Zhang Y, Du J, Zheng J, Liu J, Xu R, Shen T . EGF-reduced Wnt5a transcription induces epithelial-mesenchymal transition via Arf6-ERK signaling in gastric cancer cells. Oncotarget. 2015; 6(9):7244-61. PMC: 4466682. DOI: 10.18632/oncotarget.3133. View

11.

Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L . Immune infiltration in renal cell carcinoma. Cancer Sci. 2019; 110(5):1564-1572. PMC: 6501001. DOI: 10.1111/cas.13996. View

12.

Cai Y, Lu J, Tang F . Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMT. J Cancer. 2018; 9(3):521-527. PMC: 5820919. DOI: 10.7150/jca.22355. View

13.

Lee H, Lee S, Heo Y . Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules. 2019; 24(6). PMC: 6470598. DOI: 10.3390/molecules24061190. View

14.

McGarry D, Armstrong G, Castino G, Mason S, Clark W, Shaw R . MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Lett. 2021; 519:226-236. DOI: 10.1016/j.canlet.2021.07.039. View

15.

McGarry D, Castino G, Lilla S, Carnet A, Kelly L, Micovic K . MICAL1 activation by PAK1 mediates actin filament disassembly. Cell Rep. 2022; 41(1):111442. DOI: 10.1016/j.celrep.2022.111442. View

16.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

17.

Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan B . CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016; 14:32. PMC: 5439121. DOI: 10.1186/s12967-016-0787-y. View

18.

Farhood B, Najafi M, Mortezaee K . CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2018; 234(6):8509-8521. DOI: 10.1002/jcp.27782. View

19.

Zhao S, Min P, Liu L, Zhang L, Zhang Y, Wang Y . NEDD9 Facilitates Hypoxia-Induced Gastric Cancer Cell Migration via MICAL1 Related Rac1 Activation. Front Pharmacol. 2019; 10:291. PMC: 6458266. DOI: 10.3389/fphar.2019.00291. View

20.

Giridharan S, Rohn J, Naslavsky N, Caplan S . Differential regulation of actin microfilaments by human MICAL proteins. J Cell Sci. 2012; 125(Pt 3):614-24. PMC: 3367829. DOI: 10.1242/jcs.089367. View